NEW YORK, Could 22, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally acknowledged shareholder rights legislation agency, is investigating potential claims towards Clariant AG CLZNY, TG Therapeutics, Inc. TGTX, Coinbase International, Inc. COIN, and GoodRx Holdings, Inc. GDRX. Our investigations concern whether or not these firms have violated the federal securities legal guidelines and/or engaged in different illegal enterprise practices. Further details about every case will be discovered on the hyperlink supplied.
Clariant AG CLZNY
On February 14, 2022, Swiss chemical maker, Clariant AG, disclosed that it’s going to delay issuing This fall 2021 and full 12 months 2021 monetary outcomes due an ongoing inner investigation into potential accounting fraud.
Clariant AG is investigating inner whistleblower complaints that the corporate has recognized about since September 2021, pertaining to reserving points geared toward boosting outcomes to satisfy targets.
On this information, shares of Clariant AG ADR shares fell greater than 14% in intraday buying and selling on February 14, 2022.
For extra data on the Clariant investigation go to: https://bespc.com/cases/CLZNY
TG Therapeutics, Inc. TGTX
On November 30, 2021, TG Therapeutics issued a press launch “announc[ing] the U.S. Meals and Drug Administration (FDA) has notified the Firm that it plans to host a gathering of the Oncologic Medication Advisory Committee (ODAC) in reference to its evaluation of the pending Biologics License Utility (BLA)/supplemental New Drug Utility (sNDA) for the mix of ublituximab and UKONIQ® (umbralisib) (mixture known as U2) for the remedy of grownup sufferers with continual lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).” TG Therapeutics suggested that “[t]he FDA has notified the Firm that potential questions and dialogue matters for the ODAC embrace: the benefit-risk of the U2 mixture within the remedy of CLL or SLL, and the benefit-risk of UKONIQ in relapsed/refractory marginal zone lymphoma (MZL) or follicular lymphoma (FL). As well as, as a part of the benefit-risk evaluation, the general security profile of the U2 routine, together with antagonistic occasions (severe and Grade 3-4), discontinuations resulting from antagonistic occasions, and dose modifications, is anticipated to be reviewed”, stating that “[t]he FDA’s concern giving rise to the ODAC assembly seems to stem from an early evaluation of general survival from the UNITY-CLL trial.”
On this information, TG Therapeutics’ inventory value fell $8.16 per share, or 34.93%, to shut at $15.20 per share on November 30, 2021.
For extra data on the TG Therapeutics investigation go to: https://bespc.com/cases/TGTX
Coinbase International, Inc. COIN
On Could 10, 2022, Coinbase reported its first quarter 2022 outcomes. The corporate said it misplaced $430 million within the first quarter. Together with this, the corporate reported a first-quarter 2022 lack of $1.98 per share in comparison with the year-ago earnings of $3.05 per share.
On this information, Coinbase shares fell $18.14, or greater than 15%, in after-hours buying and selling, to open at $54.85 on Could 11, 2022.
The inventory has misplaced greater than 70% of its worth since late March, as a broader slide in tech shares and the worth of cryptocurrencies hit Coinbase significantly laborious.
For extra data on the Coinbase investigation go to: https://bespc.com/cases/COIN
GoodRx Holdings, Inc. GDRX
On Could 9, 2022, after the market closed, GoodRx introduced its first quarter 2022 monetary outcomes and withdrew its fiscal 2022 steerage. In its shareholder letter, the Firm said that “a grocery chain had taken actions that impacted acceptance of reductions from most PBMs for a subset of medication.” The Firm expects “the grocery store challenge . . . might have an estimated income influence of roughly $30 million [and] might be ongoing with out amelioration via Q2.” Consequently, GoodRx “imagine[s] it’s unlikely [it] will be capable to obtain the FY 2022 steerage” beforehand supplied.
On this information, GoodRx’s inventory fell $2.78, or 25.9%, to shut at $7.97 on Could 10, 2022, thereby injuring buyers.
For extra data on the GoodRx investigation go to: https://bespc.com/cases/GDRX
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally acknowledged legislation agency with places of work in New York, California, and South Carolina. The agency represents particular person and institutional buyers in business, securities, spinoff, and different advanced litigation in state and federal courts throughout the nation. For extra details about the agency, please go to www.bespc.com. Legal professional promoting. Prior outcomes don’t assure comparable outcomes.